FDA Rejection Hits Incyte (INCY) And Eli Lilly (LLY) Shares Hard

Incyte Corp. (INCY) and Eli Lilly & Co. (LLY) announced Friday that the received a complete response letter from the FDA for baricitinib, a treatment for moderate-to-severe rheumatoid arthritis. The FDA indicated that additional clinical data are needed to determine the most appropriate doses.

from RTT - Before the Bell http://ift.tt/2oHZ3OQ
via IFTTT